Speed and Efficiency in Designing and Building a Monoclonal Antibodies Pilot Plant - A close-up look at Pfizer's biotherapeutics plant under development in Shanbally, Ireland. - BioPharm International

ADVERTISEMENT

Speed and Efficiency in Designing and Building a Monoclonal Antibodies Pilot Plant
A close-up look at Pfizer's biotherapeutics plant under development in Shanbally, Ireland.


BioPharm International
Volume 22, Issue 3

FACILITY DESIGN CONSIDERATIONS




Because of the unpredictability of the development portfolio, two of the most important design considerations include the need for maximum operational flexibility and the speed at which changes can be made. Because site operators will be working with a number of processes in the course of a year, the ability to easily and quickly reconfigure operations and equipment is vital. These two factors affect nearly all design decisions at Shanbally—from how automation is initially configured to how buffers and media are dispensed.

The Use of Disposable Bags

Assessing project requirements was a critical initial step that covered a sweep of key factors and design and build elements carefully mapped to Shanbally's future use. Again, speed and flexibility topped the list of requirements. Designing in the ability for rapid changeover from one product to another meant the use of less hard piping in the facility. Instead, the project team opted for the use of disposable bag technology for both buffer and media, where possible. This greatly reduced the amount of piping that needs clean in place (CIP) and steam in place (SIP) treatment, which will make changeover faster and easier.

Single Downstream Processing Equipment Train


Completion of cladding and roofing in September 2008.
The relatively small production capacity needed for clinical quantities of drug substance dictated that the facility include two 2,500 L bioreactors and a single downstream processing equipment train. Much of the downstream equipment is mobile and the skids can be configured to suit differing product needs.

A key factor that influenced the plans for Shanbally was the need to achieve a design similar to the company's Phase 1 and Phase 2a pilot plant in St. Louis, MO. Because St. Louis is the focal point supporting Pfizer's biologics research and development efforts, plant similarities will permit colleagues at the two facilities to more easily share workload, improve technology transfer, and work to develop new technology as required. This will help ensure smooth technology transfer in the future from the St. Louis Pfizer Global Research & Development site to Shanbally for MAb therapeutics.

Physical Design


Final construction phase of the facility with the installation of utility equipment in October 2008.
The physical design includes a single building consisting of a manufacturing plant with a laboratory and administration block and a warehouse block configured at each end. The laboratories include a quality control (QC) laboratory and a dedicated technical services laboratory where process development work using small-scale bioreactors and purification equipment will take place. The manufacturing block has a ground floor where all utilities are located. The first floor is the main cleanroom suite where the inoculum laboratories, cell culture, harvest, purification, buffer and media prep, bulk fill, and various support activities are located. The cleanroom suite has an interstitial area over the walk-on ceiling. The third floor contains the main heating, ventilation, and air conditioning (HVAC) units.

Another consideration was effective planning for warehousing space that would be adequate for storage needs of the raw materials used in manufacturing. Storage was assessed based on the inventory requirements for our products and benchmarks with other Pfizer sites.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here